Pui CH, Yang JJ, Starvation SP, Pieters R, Schrappe M, Biondi A, et al. Childhood acute lymphoblastic leukemia: progress by means of collaboration. J Clin Oncol. 2015;33:2938–48.
Vrooman LM, Silverman LB. Therapy of childhood acute lymphoblastic leukemia: prognostic elements and scientific advances. Curr Hematol Malig Rep. 2016;11:385–94.
Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, et al. Genome-wide evaluation of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446:758–64.
Möricke A, Zimmermann M, Valsecchi MG, Stanulla M, Biondi A, Mann G, et al. Dexamethasone vs prednisone in induction remedy of pediatric ALL: outcomes of the randomized trial AIEOP-BFM ALL 2000. Blood. 2016;127:2101–12.
Schramm F, zur Stadt U, Zimmermann M, Jorch N, Pekrun A, Borkhardt A, et al. Outcomes of CoALL 07-03 research childhood ALL primarily based on mixed threat evaluation by in vivo and in vitro pharmacosensitivity. Blood Adv. 2019;3:3688–99.
Pieters R, De Groot-Kruseman H, Van Der Velden V, Fiocco M, Van Den Berg H, De Bont E, et al. Profitable remedy discount and intensification for childhood acute lymphoblastic leukemia primarily based on minimal residual illness monitoring: Examine ALL10 from the Dutch Childhood Oncology Group. J Clin Oncol. 2016;34:2591–2601.
Maxwell RR, Cole PD. Pharmacogenetic predictors of treatment-related toxicity amongst kids with acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2017;12:176–86.
Robison LL. Late results of acute lymphoblastic leukemia remedy in sufferers identified at 0-20 years of age. Hematol Am Soc Hematol Am Soc Hematol Educ Program 2011;2011:238–42.
Armstrong GT, Chen Y, Yasui Y, Leisenring W, Gibson TM, Mertens AC, et al. Discount in late mortality amongst 5-year survivors of childhood most cancers. N Engl J Med. 2016;374:833–42.
Krull KR, Hardy KK, Kahalley LS, Schuitema I, Kesler SR. Neurocognitive outcomes and interventions in long-term survivors of childhood most cancers. J Clin Oncol. 2018;36:2181–9.
McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Medication Ther. 2017;31:63–75.
Sakamoto Okay, Imamura T, Kihira Okay, Suzuki Okay, Ishida H, Morita H, et al. Low incidence of osteonecrosis in childhood acute lymphoblastic leukemia handled with ALL-97 and ALL-02 research of Japan affiliation of childhood leukemia research group. J Clin Oncol. 2018;36:900–7.
Toft N, Birgens H, Abrahamsson J, Griškevičius L, Hallböök H, Heyman M, et al. Outcomes of NOPHO ALL2008 remedy for sufferers aged 1–45 years with acute lymphoblastic leukemia. Leukemia. 2018;32:606–15.
Vora A, Goulden N, Wade R, Mitchell C, Hancock J, Hough R, et al. Therapy discount for kids and younger adults with low-risk acute lymphoblastic leukaemia outlined by minimal residual illness (UKALL 2003): a randomised managed trial. Lancet Oncol. 2013;14:199–209.
Stary J, Zimmermann M, Campbell M, Castillo L, Dibar E, Donska S, et al. Intensive chemotherapy for childhood acute lymphoblastic leukemia: outcomes of the randomized intercontinental trial ALL IC-BFM 2002. J Clin Oncol. 2014;32:174–84.
Hyakuna N, Shimomura Y, Watanabe A, Taga T, Kikuta A, Matsushita T, et al. Evaluation of corticosteroid-induced osteonecrosis in kids present process chemotherapy for acute lymphoblastic leukemia: a report from the Japanese childhood most cancers and leukemia research group. J Pediatr Hematol Oncol. 2014;36:22–29.
Gaynon PS, Lustig RH. The usage of glucocorticoids in acute lymphoblastic leukemia of childhood. Molecular, mobile, and scientific issues. J Pediatr Hematol Oncol. 1995;17:1–12.
Bostrom BC, Sensel MR, Sather HN, Gaynon PS, La MK, Johnston Okay, et al. Dexamethasone versus prednisone and each day oral versus weekly intravenous mercaptopurine for sufferers with standard-risk acute lymphoblastic leukemia: a report from the Kids’s Most cancers Group. Blood. 2003;101:3809–17.
Wellstein A, Giaccone G, Atkins MB, Sausville EA Cytotoxic Medication. In: Brunton LL, Hilal-Dandan R, Knollmann BC (eds). Goodman & Gilman’s: The Pharmacological Foundation of Therapeutics, 13e. McGraw-Hill Schooling: New York, NY, 2017. http://accessmedicine.mhmedical.com/content material.aspx?help=1162546947.
Rizzari C, Lanvers-Kaminsky C, Valsecchi MG, Ballerini A, Matteo C, Gerss J, et al. Asparagine ranges within the cerebrospinal fluid of youngsters with acute lymphoblastic leukemia handled with pegylated-asparaginase within the induction section of the AIEOP-BFM ALL 2009 research. Haematologica. 2019;104:1812–21.
Kloos RQH, Mathôt R, Pieters R, van der Sluis IM. Individualized dosing pointers for PEGasparaginase and elements influencing the clearance: a inhabitants pharmacokinetic mannequin. Haematologica. 2021;106:1254–61.
Brigitha LJ, Pieters R, van der Sluis IM. How a lot asparaginase is required for optimum end result in childhood acute lymphoblastic leukaemia? A scientific evaluation. Eur J Most cancers. 2021;157:238–49.
Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, threat stratification, and remedy of pediatric acute leukemias: an replace. J Clin Oncol. 2011;29:551–65.
Toksvang LN, Lee SHR, Yang JJ, Schmiegelow Okay. Upkeep remedy for acute lymphoblastic leukemia: fundamental science and scientific translations. Leukemia. 2022;36:1749–58.
Hryniuk W, Bush H. The significance of dose depth in chemotherapy of metastatic breast most cancers. J Clin Oncol. 1984;2:1281–8.
Hryniuk W, Levine MN. Evaluation of dose depth for adjuvant chemotherapy trials in stage II breast most cancers. J Clin Oncol. 1986;4:1162–70.
Range A, Lebellec L, Di Fiore F, Penel N, Cheymol C, Rad E, et al. FOLFIRINOX relative dose depth and illness management in superior pancreatic adenocarcinoma. Ther Adv Med Oncol. 2021;13. https://doi.org/10.1177/17588359211029825.
Lund B, Åsberg A, Heyman M, Kanerva J, Harila-Saari A, Hasle H, et al. Threat elements for remedy associated mortality in childhood acute lymphoblastic leukaemia. Pediatr Blood Most cancers. 2011;56:551–9.
DerSimonian R, Laird N. Meta-analysis in scientific trials. Management Clin Trials. 1986;7:177–88.
Balduzzi S, Rücker G, Schwarzer G. Find out how to carry out a meta-analysis with R: a sensible tutorial. Evid Primarily based Ment Well being. 2019;22:153–60.
R Core Staff. R: A language and setting for statistical computing. 2021. https://www.R-project.org/.
Lancia C, Anninga J, Spitoni C, Sydes MR, Whelan J, Hogendoorn PCW, et al. Methodology to measure the mismatch between goal and achieved acquired dose depth of chemotherapy in most cancers trials: a retrospective evaluation of the MRC BO06 trial in osteosarcoma. BMJ Open. 2019;9:e022980.
Lancia C, Anninga JK, Sydes MR, Spitoni C, Whelan J, Hogendoorn PCW, et al. A novel methodology to deal with the affiliation between acquired dose depth and survival end result: advantages of approaching remedy intensification at a extra individualised stage in a trial of the European Osteosarcoma Intergroup. Most cancers Chemother Pharm. 2019;83:951–62.
Mattano LA, Devidas M, Maloney KW, Wang C, Friedmann AM, Buckley P, et al. Favorable trisomies and ETV6-RUNX1 predict remedy in low-risk b-cell acute lymphoblastic leukemia: outcomes from Kids’s Oncology Group Trial AALL0331. J Clin Oncol. 2021;39:1540–52.
Eden T, Pieters R, Richards S. Systematic evaluation of the addition of vincristine plus steroid pulses in upkeep remedy for childhood acute lymphoblastic leukaemia – a person affected person information meta-analysis involving659 kids. Br J Haematol. 2010;149:722–33.
Angiolillo AL, Schore RJ, Kairalla JA, Devidas M, Rabin KR, Zweidler-McKay P, et al. Glorious outcomes with diminished frequency of vincristine and dexamethasone pulses in standard-risk b-lymphoblastic leukemia: outcomes from Kids’s Oncology Group AALL0932. J Clin Oncol. 2021;39:1437–47.
Conter V, Valsecchi MG, Silvestri D, Campbell M, Dibar E, Magyarosy E, et al. Pulses of vincristine and dexamethasone along with intensive chemotherapy for kids with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial. Lancet. 2007;369:123–31.
De Moerloose B, Suciu S, Bertrand Y, Mazingue F, Robert A, Uyttebroeck A, et al. Improved end result with pulses of vincristine and corticosteroids in continuation remedy of youngsters with common threat acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): report of the EORTC randomized section 3 trial 58951. Blood. 2010;116:36–44.
Yang W, Cai J, Shen S, Gao J, Yu J, Hu S, et al. Pulse remedy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, section 3, non-inferiority trial. Lancet Oncol. 2021;22:1322–32.
Seibel NL, Steinherz PG, Sather HN, Nachman JB, Delaat C, Ettinger LJ, et al. Early postinduction intensification remedy improves survival for kids and adolescents with high-risk acute lymphoblastic leukemia: a report from the Kids’s Oncology Group. Blood. 2008;111:2548–55.
Richards S, Burrett J, Hann I, Chessells J, Hill F, Bailey C. Improved survival with early intensification: mixed outcomes from the Medical Analysis Council childhood ALL randomised trials, UKALL X and UKALL XI. Medical Analysis Council Working Celebration on Childhood Leukaemia. Leukemia. 1998;12:1031–6.
Usami I, Imamura T, Takahashi Y, Suenobu S, Hasegawa D, Hashii Y, et al. Discontinuation of L-asparaginase and poor response to prednisolone are related to poor end result of ETV6-RUNX1-positive pediatric B-cell precursor acute lymphoblastic leukemia. Int J Hematol. 2019;109:477–82.
Gupta S, Wang C, Raetz EA, Schore R, Salzer WL, Larsen EC, et al. Influence of asparaginase discontinuation on end result in childhood acute lymphoblastic leukemia: a report from the Kids’s Oncology Group. J Clin Oncol. 2020;38:1897–905.
Gottschalk Højfeldt S, Grell Okay, Abrahamsson J, Lund B, Vettenranta Okay, Jónsson ÓG, et al. Relapse threat following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia. Blood. 2021;137:2373–82.
Ramakers-Van Woerden NL, Pieters R, Loonen AH, Hubeek I, Van Drunen E, Bema Beverloo H, et al. TEL/AML1 gene fusion is expounded to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood. 2000;96:1094–9.
Stams WAG, Den Boer ML, Beverloo HB, Meijerink JPP, Stigter RL, Van Wering ER, et al. Sensitivity to L-asparaginase isn’t related to expression ranges of asparagine synthetase in t(12;21)+ pediatric ALL. Blood. 2003;101:2743–7.
Stams WAG, Den Boer ML, Holleman A, Appel IM, Beverloo HB, Van Wering ER, et al. Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative however not TEL-AML1-positive pediatric acute lymphoblastic leukemia. Blood. 2005;105:4223–5.
Keefe DA, Capizzi RL, Rudnick SA. Methotrexate cytotoxicity for L5178Y/Asn- lymphoblasts: relationship of dose and period of publicity to tumor cell viability. Most cancers Res. 1982;42:1641–5.
Ackland SP, Schilsky RL. Excessive-dose methotrexate: a essential reappraisal. J Clin Oncol. 1987;5:2017–31.
Clarke M, Gaynon P, Hann I, Harrison G, Masera G, Peto R, et al. CNS-directed remedy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials. J Clin Oncol. 2003;21:1798–809.
Lopez-Lopez E, Autry RJ, Smith C, Yang W, Paugh SW, Panetta JC, et al. Pharmacogenomics of intracellular methotrexate polyglutamates in sufferers’ leukemia cells in vivo. J Clin Make investments. 2020;130:6600.
Matloub Y, Lindemulder S, Gaynon PS, Sather H, La M, Broxson E, et al. Intrathecal triple remedy decreases central nervous system relapse however fails to enhance event-free survival in comparison with intrathecal methotrexate: outcomes of the Kids’s Most cancers Group (CCG) 1952 research for standard-risk acute lymphoblastic leukemia, reported by the Kids’s Oncology Group. Blood. 2006;108:1165–73.
Salzer WL, Burke MJ, Devidas M, Dai Y, Hardy KK, Kairalla JA, et al. Influence of intrathecal triple remedy versus intrathecal methotrexate on disease-free survival for high-risk B-lymphoblastic leukemia: kids’s oncology group research AALL1131. J Clin Oncol. 2020;38:2628–38.
Schrappe M, Bleckmann Okay, Zimmermann M, Biondi A, Möricke A, Locatelli F, et al. Diminished-intensity delayed intensification in standard-risk pediatric acute lymphoblastic leukemia outlined by undetectable minimal residual illness: outcomes of a global randomized trial (AIEOP-BFM ALL 2000). J Clin Oncol. 2018;36:244–53.
Pieters R, de Groot-Kruseman H, Fiocco M, Verwer F, Van Overveld M, Sonneveld E, et al. Improved end result for ALL by prolonging remedy for IKZF1 deletion and lowering remedy for different threat teams. J Clin Oncol. 2023. https://doi.org/10.1200/JCO.22.02705.
Veerman AJ, Kamps WA, van den Berg H, van den Berg E, Bökkerink JP, Bruin MC, et al. Dexamethasone-based remedy for childhood acute lymphoblastic leukaemia: outcomes of the possible Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol. 2009;10:957–66.
Oh BLZ, Lee SHR, Foo KM, Chiew KH, Seeto ZZL, Chen ZW, et al. Profitable toxicity discount throughout delayed intensification within the non-high-risk arm of Malaysia-Singapore Acute Lymphoblastic Leukaemia 2010 research. Eur J Most cancers. 2021;142:92–101.
Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grümayer R, Möricke A, et al. Molecular response to remedy redefines all prognostic elements in kids and adolescents with B-cell precursor acute lymphoblastic leukemia: leads to 3184 sufferers of the AIEOP-BFM ALL 2000 research. Blood. 2010;115:3206–14.
Stow P, Key L, Chen X, Pan Q, Neale GA, Coustan-Smith E, et al. Medical significance of low ranges of minimal residual illness on the finish of remission induction remedy in childhood acute lymphoblastic leukemia. Blood. 2010;115:4657–63.
Zawitkowska J, Lejman M, Romiszewski M, Matysiak M, Ćwiklińska M, Balwierz W, et al. Outcomes of two consecutive remedy protocols in Polish kids with acute lymphoblastic leukemia. Sci Rep. 2020;10. https://doi.org/10.1038/S41598-020-75860-6.
Pieters R, De Lorenzo P, Ancliffe P, Aversa LA, Brethon B, Biondi A, et al. Final result of infants youthful than 1 yr with acute lymphoblastic leukemia handled with the interfant-06 protocol: outcomes from a global section iii randomized research. J Clin Oncol. 2019;37:2246–56.
O’Connor D, Enshaei A, Bartram J, Hancock J, Harrison C, Hough R, et al. Genotype-specific minimal residual illness interpretation improves stratification in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2018;36:34–43.
